Skip to main content

Advertisement

Table 3 Combined clinicopathologic analysis according to the various criteria

From: Comparative analysis of the EGFR, HER2, c-MYC, and MET variations in colorectal cancer determined by three different measures: gene copy number gain, amplification status and the 2013 ASCO/CAP guideline criterion for HER2 testing of breast cancer

Characteristics Amplification GCN gain 2013 ASCO/CAP guideline
Negative Positive P CN< 4 4 ≤CN P Negative Equivocal or positive P
Location    0.403    0.241    0.213
 Right colon 79 (84.9%) 14 (15.1%)   69 (74.2%) 24 (25.8%)   67 (72.0%) 26 (28.0%)  
 Left colon 100 (78.7%) 27 (21.3%)   81 (63.8%) 46 (36.2%)   77 (60.6%) 50 (39.4%)  
 Rectum 89 (78.1%) 25 (21.9%)   75 (65.8%) 39 (34.2%)   74 (64.9%) 40 (35.1%)  
pTNM stage    0.708    0.124    0.257
 I–III 218 (79.9%) 55 (20.1%)   189 (69.2%) 84 (30.8%)   182 (66.7%) 91 (33.3%)  
 IV 50 (82.0%) 11 (18.0%)   36 (59.0%) 25 (41.0%)   36 (59.0%) 25 (41.0%)  
MSI status (n = 323)    0.097    0.004    0.002
 MSS/MSI-L 235 (79.4%) 61 (20.6%)   194 (65.5%) 102 (34.5%)   188 (63.5%) 108 (36.5%)  
 MSI-H 25 (92.6%) 2 (7.4%)   25 (92.6%) 2 (7.4%)   25 (92.6%) 2 (7.4%)  
  1. MSI microsatellite instability, MSS microsatellite instability stable, MSI-L microsatellite instability-low, MSI-H microsatellite instability-high, GCN gene copy number, CN copy number, ASCO/CAP American Society of Clinical Oncology/College of American Pathologists